Yahoo Finance

Anjalee Khemlani

Senior Reporter

Anjalee Khemlani is an award-winning healthcare and business reporter at Yahoo Finance covering the entire healthcare sector, including pharma, health tech, providers, insurers, PBMs and health equity. Khemlani has previously worked for a variety of media organizations that include startup digital, legacy daily news, international broadcast and local radio, and has been a guest on global broadcast and radio stations covering the Covid-19 pandemic and global public health.

Experts: How Trump's healthcare picks could impact global health

President-elect Donald Trump's nominees for the country's top health agencies and his previous track record in office have sparked concerns globally about a potential rise in "anti-science" views and the defunding of global public health efforts.

4 hours ago
Amgen shows 20% weight loss in once-monthly injectable MariTide

Amgen's latest once-monthly weight loss drug data looks "OK," analysts say, as its path to approval still remains murky.

10 hours ago

NONOF

NVO
Allurion launches compounded GLP-1 program as FDA aims to end access

Allurion joins the pack to offer compounded GLP-1 access for patients.

yesterday

LLY

ALUR
How Robert F. Kennedy Jr. could impact the healthcare sector as secretary of health

Robert F. Kennedy Jr.'s nomination to lead HHS is causing cautious concern among investors. Here's which companies and stocks could be impacted, as well as which policies are in line for disruption.

8 days ago

JNJ

NONOF
The weight-loss frenzy is making some pharma stocks much more volatile. Will the drama continue?

The excitement around the new weight-loss industry is overtaking other disease areas and portfolios for publicly traded companies.

10 days ago

NONOF

NVO
How analysts are reacting to RFK Jr. as Trump's HHS pick

President-elect Donald Trump has selected Robert F. Kennedy Jr. for the position of Secretary of Health & Human Services (HHS). The appointment has drawn significant attention due to Kennedy Jr.'s controversial stance on vaccines, including his designation as one of the "Disinformation Dozen" during the COVID-19 pandemic. Following the announcement, vaccine-related stocks experienced a notable decline. Yahoo Finance Senior Health Reporter Anjalee Khemlani analyzes the implications of this appointment and shares reactions from market analysts regarding its potential impact on the healthcare sector. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Angel Smith

11 days ago

MRNA

SNY
Analysts think Wall Street's reaction to the RFK Jr. news is 'overdone.' Sort of.

President-elect Donald Trump tapped Robert F. Kennedy Jr. to lead the US Health and Human Services Department. Vaccine stocks slid on the news.

11 days ago

SNY

SNYNF
Hims & Hers launches GLP-1 tracker in response to FDA's shortage decision

Hims & Hers is launching a tracker of GLP-1 shortages to push back against the FDA's recent moves to end compounding copycats of the blockbuster drugs.

13 days ago

HIMS

NONOF
Novavax stock plunges after quarterly earnings, but company sees hope in licensing deals

Novavax sees Sanofi deal as path forward for company into profitability.

14 days ago

MRNA

NVAX
Gilead increases 2024 outlook, expects new drug filing by end of year

Gilead reported strong Q3 results and expects a consistent growth trajectory for the coming years.

19 days ago

GILD
Novo Nordisk, in a mixed-bag earnings report, beat expectations on Wegovy sales but tightened its 2024 outlook

Novo Nordisk reported mixed Q3 earnings, but GLP-1 drugs contributed to revenue strength. The company also adjusted its year-end outlook. Wall Street wasn't cheery about that.

20 days ago

NONOF

NVO
Eli Lilly plans to begin advertising weight-loss drug Zepbound

Eli Lilly is preparing to advertise its blockbuster weight-loss drug Zepbound for the first time ever.

27 days ago

LLY

NONOF
Eli Lilly stock sinks after Q3 earnings miss Wall Street expectations

Eli Lilly's stock valuation sank by $100 billion Wednesday morning after the pharma giant reported third quarter earnings.

27 days ago

BIIB

NONOF
Pfizer CEO: The activist investors are 'too late'

Pfizer had a "constructive" meeting with activist investor Starboard Value last week and spoke publicly about it for the first time on Tuesday.

28 days ago

BNTX

PFE
Pfizer raises full-year guidance by $1.5 billion amid activist investor pressure

Pfizer posted strong earnings in the third quarter as investors worry about the stock's value.

28 days ago

BMY

CELG-RT
Philips stock sinks 16% on lower full-year guidance, China drags on earnings

Philips had mixed earnings, but its stock slumped from ongoing pressure in the Chinese market.

29 days ago

PHG

RYLPF
Why compounders and telehealth providers are undeterred by the potential end of the weight-loss drug shortage

Online health platforms continue to advertise access to copycat versions of blockbuster weight-loss drugs Wegovy and Zepbound despite the long-term threat to business.

30 days ago

COST

LLY
In Vegas, health tech leaders adopt a more realistic approach to AI

AI in healthcare has reached a point where the promise of digital health may finally be fulfilled. Or has it? A dispatch from the HLTH conference in Vegas.

last month

MSFT

GOOG
Walmart joins retail pharmacy push in same-day prescription delivery

Walmart is entering the online prescription delivery world, and trying to one-up competitors with same-cart service for patients.

last month

WMT

WBA
Salesforce, Blue Shield CA partner to create an AI-focused healthcare approval system

Salesforce and Blue Shield of California have co-created an AI system they say will not automatically deny care claims for patients.

last month

HUM

CRM

News

Life

Entertainment

Finance

Sports

New on Yahoo

Anjalee Khemlani

Most Recent

Experts: How Trump's healthcare picks could impact global health

Amgen shows 20% weight loss in once-monthly injectable MariTide

Allurion launches compounded GLP-1 program as FDA aims to end access

How Robert F. Kennedy Jr. could impact the healthcare sector as secretary of health

The weight-loss frenzy is making some pharma stocks much more volatile. Will the drama continue?

How analysts are reacting to RFK Jr. as Trump's HHS pick

Analysts think Wall Street's reaction to the RFK Jr. news is 'overdone.' Sort of.

Hims & Hers launches GLP-1 tracker in response to FDA's shortage decision

Novavax stock plunges after quarterly earnings, but company sees hope in licensing deals

Gilead increases 2024 outlook, expects new drug filing by end of year

Novo Nordisk, in a mixed-bag earnings report, beat expectations on Wegovy sales but tightened its 2024 outlook

Eli Lilly plans to begin advertising weight-loss drug Zepbound

Eli Lilly stock sinks after Q3 earnings miss Wall Street expectations

Pfizer CEO: The activist investors are 'too late'

Pfizer raises full-year guidance by $1.5 billion amid activist investor pressure

Philips stock sinks 16% on lower full-year guidance, China drags on earnings

Why compounders and telehealth providers are undeterred by the potential end of the weight-loss drug shortage

In Vegas, health tech leaders adopt a more realistic approach to AI

Walmart joins retail pharmacy push in same-day prescription delivery

Salesforce, Blue Shield CA partner to create an AI-focused healthcare approval system